Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer Inc. : Pfizer Gets Positive Opinion from EMA on Leukemia Drug Bosutinib

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/18/2013 | 02:46pm CEST
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said the European Medicines Agency (EMA) issued a positive opinion about the conditional marketing authorization of its cancer drug bosutinib in the European Union for the treatment of adult patients with certain types of leukemia.

Pfizer said the positive opinion was adopted by the Committee for Medicinal Products for Human Use and relates to chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib aren't considered appropriate treatment options.

Conditional approvals in the EU are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit.

Bosutinib is an oral, once-daily, kinase inhibitor, which limits cancer cell growth by inhibiting certain signaling pathways.

Pfizer noted that chronic myelogenous leukemia accounts for 15% of all leukemia cases and that, despite the availability of existing treatments for the condition, there remains a need for additional treatment options.

"We believe that bosutinib, if approved by the European Commission, would represent an important option for patients with CML who have progressed on prior treatment and are not candidates for alternative treatments," said Mace Rothenberg, senior vice president of clinical development and medical affairs at the Pfizer Oncology Business Unit. "We believe many doctors and CML patients will find this treatment, if approved, to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen."

Shares were flat at $26.83 in recent premarket trading. The stock has risen 22% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
04/25Shire willing to back $64 billion Takeda bid, market signals doubts
RE
04/25PFIZER : Invites Public to Listen to Webcast of April 26 Annual Meeting of Share..
AQ
04/25ONCONOVA THERAPEUTICS : Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at Amer..
AQ
04/25MERCK AND : adds affinity optimization to nanoscale synthesis system
AQ
04/24Women's Health Market Analysis on Segment, Trend, Growth, Volume, Size, Globa..
AQ
04/24Biocon to gain as Pfizer’s Herceptin biosimilar delayed further
AQ
04/24PFIZER : hits stumbling block on Herceptin rival, but wins breakthrough status o..
AQ
04/24PFIZER : Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococca..
AQ
04/24PFIZER : MYLOTARG Approved in the EU for the Treatment of Previously Untreated, ..
AQ
04/24PFIZER : CD33-positive AML drug approved in Europe
AQ
More news
News from SeekingAlpha
2015Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update 
2015Antibiotics Stocks To Benefit From 21st Century Cures Act 
2015ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case 
2015DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb 
2015Pfizer's GL-2045 an Orphan Drug for CIDP 
Financials ($)
Sales 2018 54 460 M
EBIT 2018 20 816 M
Net income 2018 12 632 M
Debt 2018 23 675 M
Yield 2018 3,71%
P/E ratio 2018 17,01
P/E ratio 2019 15,55
EV / Sales 2018 4,45x
EV / Sales 2019 4,24x
Capitalization 219 B
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 40,1 $
Spread / Average Target 8,2%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC218 908
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398